Search
Metandienone
go.drugbank.com/drugs/DB13586ApprovedWithdrawnIt was introduced to the market in the 1960s but later discontinued and withdrawn from the market. … Although it is prohibited in and outside competition by the World Anti-Doping Agency, metandienone continues to be marketed and misused as a performance-enhancing drug in sports.
Categories: Androgens for Topical Use, Anabolic Agents for Systemic UseInfluenza A virus A/Hong Kong/2671/2019 IVR-208 (H3N2) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB15704ApprovedInvestigationalVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.
Mixtures: Vaxigrip Tetra, Suspension for Injection in Pre-filled SyringeDihydroergocristine
go.drugbank.com/drugs/DB13345Approved[A32879] To know more about ergoloid mixtures, please visit [DB01049]. … [L2637] It is a semisynthetic ergot alkaloid and thus, it is characterized by a structural skeleton formed by an alkaloid ergoline.
Categories: Heterocyclic Compounds with 4 or More RingsRegorafenib
go.drugbank.com/drugs/DB08896ApprovedInvestigationalApproved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017. … It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012.
Solifenacin
go.drugbank.com/drugs/DB01591ApprovedInvestigationalSolifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency.
Categories: Drugs for Urinary Frequency and IncontinenceRoxadustat
go.drugbank.com/drugs/DB04847ApprovedInvestigationalIt works by reducing the breakdown of the hypoxia-inducible factor (HIF), which is a transcription factor that stimulates red blood cell production in response to low oxygen levels. … Roxadustat is a first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor used to treat anemia associated with chronic kidney disease.
Lurasidone
go.drugbank.com/drugs/DB08815ApprovedInvestigationalFood and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. … Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeLactitol
go.drugbank.com/drugs/DB12942Approved[A190915,A190918] Pizensy, an oral lactitol powder for solution, was approved by the FDA for use in chronic idiopathic constipation in February 2020.[L11803] … [A190912] Clinically, lactitol has been investigated for use as an osmotic laxative and, along with other non-absorbable disaccharides such as [lactulose], in the treatment of hepatic encephalopathy in
Categories: Drugs for Constipation, Compounds used in a research, industrial, or household settingTiaprofenic acid
go.drugbank.com/drugs/DB01600ApprovedIt belongs to the _arylpropionic acid_ (profen) group of nonsteroidal anti-inflammatory drugs (NSAIDs).
Tolrestat
go.drugbank.com/drugs/DB02383ApprovedWithdrawnWhile it was approved for marketed in several countries, it failed a Phase III trial in the U.S. due to toxicity and never received FDA approval. … It was sold under the tradename Alredase but was discontinued by Wyeth in 1997 because of the risk of severe liver toxicity and death.